Company profile: TargEDys
1.1 - Company Overview
Company description
- Provider of functional and medical foods and medical products that harness the microbiota and hormone-mimetic proteins to regulate appetite and treat eating disorders such as hyperphagia and anorexia. Portfolio includes Hafnia alvei HA4597 and LpWJL precision probiotics, PreciBiomic oxytocin-mimetic strains for stress/anxiety, and Symbiosys Satylia distributed by Biocodex in select European countries.
Products and services
- Hafnia alvei HA4597: A strain-specific precision probiotic engineered to regulate appetite and support weight loss by producing ClpB that activates satiety pathways via microbiota-driven signaling
- PreciBiomic strains: Receptor-targeted bacterial assemblies producing oxytocin mimetic proteins to reduce stress and anxiety by activating OT-R receptors for neuroendocrine modulation
- Lactiplantibacillus plantarum WJL (LpWJL): Somatotropic-axis-driven microbial component that promotes growth and nutrition optimization through stimulation of growth hormone pathways across diverse nutrition fields
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TargEDys
Infinant Health
HQ: United States
Website
- Description: Provider of infant gut microbiome solutions, offering Evivo Powder, a daily supplement for infants fed any amount of breast milk to establish a protective gut microbiome and support healthy immune function, and B. infantis EVC001, a bacterial strain discovered by Infinant Health and proven pivotal to infant immune health, particularly when combined with breast milk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinant Health company profile →
Xycrobe
HQ: United States
Website
- Description: Provider of early-stage biotechnology research and development leveraging extensive human microbiome data to develop novel therapies for clinical applications, with innovations that utilize microbes as delivery vehicles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xycrobe company profile →
Vedanta Biosciences
HQ: United States
Website
- Description: Provider of microbiome-derived therapies that modulate the gut microbiota to address immune and infectious diseases via orally administered defined bacterial consortia. Pipeline includes VE303 for preventing Clostridioides difficile infection recurrence (Phase 2 met primary efficacy endpoint), VE202 for IBD, and VE707 for MDROs (including CRE, ESBL, VRE); backed by CARB-X research grants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vedanta Biosciences company profile →
Kallyope
HQ: United States
Website
- Description: Provider of medicines developed using the science of gut-brain biology to transform human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kallyope company profile →
BioCare Copenhagen
HQ: Denmark
Website
- Description: Provider of dietary supplements with microbial components for gastrointestinal problems, infections, and immune enhancement; offers medical nutrition, early life nutrition, pharma solutions, and nutrition improvement. Products include Humiome B2, supporting gut health by delivering a high percentage of vitamin B2 to the colon.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCare Copenhagen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TargEDys
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TargEDys
2.2 - Growth funds investing in similar companies to TargEDys
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TargEDys
4.2 - Public trading comparable groups for TargEDys
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →